Petros Grivas, MD, PhD

Closing out their panel on advanced bladder cancer management, key opinion leaders share their excitement for future evolutions within the treatment landscape.

Expert perspectives on novel treatment strategies in the second-line treatment setting of advanced bladder cancer.

Leaders in bladder cancer management consider factors that aid in their selection of second-line therapy.

In light of individual patient needs, perspectives are shared on the roles of palliative radiation and treatment breaks in the setting of advanced bladder cancer.

A brief discussion on optimal follow-up practices with patients on therapy for advanced bladder cancer.

Following a patient with bladder cancer who had a partial response to frontline therapy, panelists consider the branching treatment pathway.

Genitourinary cancer experts share insight on best practices in educating patients on treatment schedules and adverse events when receiving therapy for advanced bladder cancer.

Focused discussion on the optimal use of radiation therapy strategies, alone or in combination with systemic therapy, for patients with advanced bladder cancer.

Key opinion leaders in bladder cancer consider the evolving role of chemoradiation in patients with node-positive disease.

Expert perspectives on first-line treatment options available to patients with advanced bladder cancer who are ineligible for cisplatin-based chemotherapy.

Centering focus on the first-line treatment armamentarium, key opinion leaders consider factors that aid in the selection of best therapy for patients with advanced bladder cancer.

A brief discussion on supportive care available to patients with bladder cancer and the role it plays within the treatment pathway.

Shared insight on the standard work-up and staging practices used when a patient presents with newly diagnosed bladder cancer.

Expert panelists review a patient presentation of bladder cancer and consider the typical signs and symptoms that may lead to a diagnosis.

Closing out their review of metastatic urothelial carcinoma management, panelists share what they most look forward to in the evolving treatment landscape.

Focused discussion on the optimal selection and use of antibody-drug conjugate therapies in patients with metastatic urothelial carcinoma.

Expert perspectives on treatment sequencing pathways in metastatic urothelial carcinoma, with deference to recent trial data for both IO and ADC therapies.

The panel reviews a clinical scenario of metastatic urothelial carcinoma where the patient is not eligible for cisplatin treatment.

A comprehensive review of maintenance therapy strategies following chemotherapy in the context of optimizing patient outcomes.

Centering discussion on a clinical scenario of metastatic urothelial carcinoma, panelists determine which first-line regimen they would utilize prior to maintenance therapy.

A panel of experts reviews key clinical trial data supporting use of maintenance therapy in metastatic urothelial carcinoma.

Shared insight on the broader benefits of maintenance therapy in metastatic urothelial carcinoma and the mainstay agents in this setting.

Expert oncologists provide a comprehensive overview of treatment options available to patients with metastatic urothelial carcinoma.

A brief review of both neoadjuvant and adjuvant treatment options available to patients with localized bladder cancer.

Opening their discussion on urothelial carcinoma management, panelists highlight risk factors, symptoms, and staging practices in this setting.

Experts highlight emerging data and novel regimens that have the biggest potential to impact treatment and management of patients with urothelial cancer.

Experts comment on the utility of PARP inhibitors in UC and discuss data presented at ASCO GU 2022.

Guru Sonpavde, MD, introduces emerging antibody-drug conjugates for treating metastatic UC, and reviews recent ASCO GU 2022 data on these regimens.

Petros Grivas, MD, PhD, transitions the panel discussion to focus on clinical trial data on combination immunotherapy versus platinum chemotherapy regimens that were recently presented at ASCO GU 2022.

The panel summarizes unmet needs in frontline maintenance therapy for UC and comments on ongoing trials for novel treatment regimens.